Trial · NCT02121756
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | Baseline to week 12 | Change in plasma levels of sCD14 from baseline to week 12 |
| Primary | Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | baseline to week 12 | Change in Plasma levels of sCD163 from baseline to week 12 |
| Primary | Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | baseline to week 12 | Change in Plasma levels of IL-6 from baseline to week 12 |
| Secondary | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo. |
| Secondary | Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | First 12 weeks of dipyridamole treatment | Grade 2 or higher adverse events and treatment discontinuations |
| Secondary | Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | Baseline to week 12 | To assess whether Dipyridamole reduces the proportion of cycling CD4+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole. |
| Secondary | Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing HLA-DR and CD38 after 12 weeks of DP treatment to placebo. |
| Secondary | Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD8+ T cells co-expressing HLA-DR and CD38 after 12 weeks of Dipyridamole treatment to placebo. |
| Secondary | Immune System Activation Assessed by the Proportion of CD4+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment to Placebo | Baseline to week 12 | To compare changes in the level of T cell immune activation as measured by the proportion of CD4+ T cells co-expressing CD69 and CD25 after 12 weeks of Dipyridamole treatment to placebo. |
| Secondary | Cellular Immune Activation: Change in the Proportion of Cycling CD8+ T Cells | Baseline to week 12 | To assess whether Dipyridamole reduces the proportion of cycling CD8+ T cells as measured by Ki-67 expression at baseline and after treatment with Dipyridamole. |
| Secondary | Systemic Inflammatory Biomarkers: Change in the Levels of sTNFαR | Baseline to week 12 | To compare changes in the levels of sTNFαR after 12 weeks of dipyridamole treatment to placebo |
| Secondary | Systemic Inflammatory Biomarkers: Change in the Levels of TNFα | Baseline to week 12 | To compare changes in the levels of TNFα after 12 weeks of dipyridamole treatment to placebo |
| Secondary | Systemic Inflammatory Biomarkers: Change in the Levels of hsCRP | Baseline to week 12 | To compare changes in the levels of hsCRP after 12 weeks of dipyridamole treatment to placebo |
| Secondary | Coagulation Biomarkers: Change in the Levels of D-dimer | Baseline to week 12 | To compare changes in the levels of D-dimer after 12 weeks of dipyridamole treatment to placebo |
| Secondary | Changes in Brachial Artery Flow-mediated Dilation (FMD) | Baseline to week 12 | To compare % change at tmax in brachial artery flow-mediated dilation (FMD) after 12 weeks of dipyridamole treatment to placebo |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02121756/registered